Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-in-collaboration-with-west-china-school-of-medicine-co-led-world-s-first-in-human-clinical-trial-using-crispr-technology-for-lung-cancer-confirmed-gene-edited-t-cell-therapy-is-safe-and-feasible-in-treatment-of-advanced-nsclc
https://www.med.cuhk.edu.hk/press-releases/cuhk-in-collaboration-with-west-china-school-of-medicine-co-led-world-s-first-in-human-clinical-trial-using-crispr-technology-for-lung-cancer-confirmed-gene-edited-t-cell-therapy-is-safe-and-feasible-in-treatment-of-advanced-nsclc

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Professor Tony MOK from the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) and Professor LU You from West China School of Medicine at The Sichuan University co-led the world’s first-in-human Phase I clinical trial investigating the safety and feasibility of CRISPR gene-edit therapy as a treatment option for patients with late stage lung cancer. Research team recruited 22 advanced Non-small-cell lung carcinoma (NSCLC) patients and isolate the T cell (a form of white blood cell) from peripheral blood. After gene-editing by CRISPR, the T cells that were reinfused back to patient may have the ability to attack cancer cell.  Objective of the study is to demonstrate safety and feasibility. Results demonstrated CRISPR technology is safe and feasible as patients showed no severe adverse events and the frequency of off-target events was only 0.05%. This opens a new chapter in the history of lung cancer immunotherapy. The findings were recently published on-line in the international medical journal Nature Medicine.

 

Inhibiting PD-1 protein is the key to treat advanced NSCLC

 

Lung cancer is the most common cancer in the world, accounting for 1.6 million deaths every year. In Hong Kong, lung cancer is also the leading cause of cancer deaths and the second most common cancer with over 4,000 new cases every year. NSCLC accounts for about 80% of all lung cancers. 

 

Professor Tony MOK Shu Kam, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology said, “Anti-PD-1 checkpoint inhibitors are currently the standard first-line therapy for advanced NSCLC. PD-1 is a protein on the surface of our T cells in the immune system.  When it binds with ligand PD-L1 from cancer cells, it prevents the immune system from killing cancer cells. The inhibitors serve the purpose to prevent the binding from taking place and allow the immune system to do its work and kill cancer cells. Based on the same theory, we are exploring the use of an alternative tool – CRISPR technology to edit T cell and disable PD-1 on T cell from functioning.”

 

World’s First-in-human Clinical Trial Using CRISPR Technology for Lung Cancer

 

Professor LU You is the pioneer in clinical application of CRISPR technology in China, and in partnership with Professor Tony MOK who is also a visiting professor to West China School of Medicine, they designed the world’s first-in-human clinical trial with a team of scientists and oncologists from China. The research team recruited 22 advanced NSCLC patients who had failed multiple lines of therapy between 2016 and 2018 for the study. They implemented CRISPR-Cas9 technology to disrupt PD-1 gene in T cells. Total of 17 patients had sufficient T cells for the editing process but five dropped out because of disease progression and other reasons. Researchers extracted T cells from patients, edited them with CRISPR and re-infused as therapeutic T cells.

 

As per report in Nature Medicine, the median time to prepare the T cells for reinfusion for these 17 patients was 25 days.  None of the 12 patients who received the treatment had severe or life-threatening adverse events. Given the risk of off-target mutations, which are the nonspecific and unintended genetic modifications that may potentially be harmful, whole-genome sequencing and next generation sequencing were performed on edited T cells before and after infusion.  The median mutation frequency of off-target events was only 0.05%. The finding is strongly supportive of the fact that T cell gene-editing by CRISPR is safe.

 

Treatment efficacy was limited as this was not the objective of study and most patients were at very late stage of their illness. The best response was seen in a 55-year-old woman whose tumour mass initially shrank, and her disease remained stable for almost 75 weeks before finally progressing.

 

“To get a new technology or therapy into the clinic we first need to ask if it is feasible and if we can do it safely. A new chapter is opening in the cancer immunotherapy field, combining the cutting-edge technologies of CRISPR gene editing and T cell therapy and it is still in the early stage of development,” said Professor Tony MOK.

 

In regard to future improvement in efficacy, Professor LU You commented, “Gene-edited cell therapy is definitely a potential new direction for treatment of lung cancer. An important point for future improvement gene editing therapy is to enrol patients earlier when the T cells are still in healthy state. At the end of the day, it is the T cell that does the work, and we need healthy T cells.”

More Press Releases

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.